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Background. The early pathophysiological 
mechanisms of diastolic dysfunction are 
not understood well. Hydrogen sulfide is 
an important endogenous gaseous trans-
mitter that can influence heart remodeling. 
The aim was to determine total plasma 
sulfide (TPS) levels, as a surrogate marker 
of hydrogen sulfide, in patients with mild 
diastolic dysfunction.
Methods. Total plasma sulfide and N-ter-
minal pro brain-type natriuretic peptide 
(NT-proBNP) levels were determined in 
ambulatory patients with arterial hyper-
tension or diabetes mellitus and echocar-
diographically mild to moderate diastolic 
dysfunction.
Results. Twenty-four patients were in-
cluded: nine with normal diastolic func-
tion (Grade 0), eight with an impaired 
relaxation pattern (Grade 1), and seven 
with a pseudo-normalized pattern (Grade 
2). TPS levels were highest in patients with 
normal diastolic function (Grade 0), and 
lowest in patients with Grade 2 diastolic 
dysfunction, with this difference between 
Grade 0 and Grade 2 showing statistical 
significance (p = 0.017). NT-proBNP lev-
els showed the reverse behavior, with this 
difference again showing statistical signifi-
cance (p = 0.042).
Conclusions. Total plasma sulfide levels 
decrease with worsening of diastolic func-
tion from normal to moderate diastolic 
dysfunction. 
Key words: total plasma sulfide, hydrogen 
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INTRODUCTION
Heart failure with preserved ejection 
fraction is a new condition that has only 
been described in recent years. (1) One of 
its defining criteria is diastolic dysfunc-
tion. It has gained a lot of attention since 
its incidence has been rising and there is 
still no solid guidelines for treatment or 
prevention. There remains a huge gap in 
our understanding of the pathological and 
pathophysiological processes during the 
primary and advancing stages of diastolic 
dysfunction. The key event is myocyte hy-
pertrophy and collagen deposition, which 
causes diastolic relaxation problems. Insuf-
ficient diastolic relaxation results in higher 
left ventricular filling pressure, left atrial 
stretch, and pulmonary congestion. Clini-
cally, all of these represent the exercise 
dyspnea and signs of pulmonary conges-
tion seen in cases of advanced heart fail-
ure. (2) 
Hydrogen sulfide (H2S) is a gas that has the 
characteristic odor of rotten eggs, and it is 
generally known for its toxicity. (3) H2S is 
toxic because it binds to cytochrome c oxi-
dase, and therefore inhibits the mitochon-
drial respiratory chain. As well as showing 
toxicity, H2S has an important role in sign-
aling at the cellular level. H2S can modu-
late vascular tone and neuronal function, 
and it can also be cryoprotective during 
ischemia. (4) H2S has recently emerged as 
an important gaseous transmitter in mam-
mals, along with nitric oxide and carbon 
monoxide. (5) 
In mammals, H2S is synthesized from 
the sulfur-containing amino acid L-
cysteine through the activities of either 
cystathionine-β-synthase or cystathionine-
γ-lyase, both of which require vitamin B6 
as a cofactor. (5) A further mitochondrial 
enzyme has been described recently to 
also synthesize H2S: 3-mercaptopyruvate 
sulfurtransferase. (6) In conjunction with 
cysteine aminotransferase, this enzyme 
also contributes significantly to the genera-
tion of H2S. All three of these enzymes are 
expressed in smooth muscle and endothe-
lium. 
Since H2S shows not only complex pro-
duction, but also has a complex influence 
on various tissues, it has been studied ex-
tensively in recent years. Although H2S is 
a gas, it is very short-lived due to its dis-
solving to form a weak acid: HS– and S2– 
(although S2– is negligible at physiological 
pH). Here, we will use the term H2S only 
for the gaseous form, and in all other in-
stances, the term sulfide will refer to the 
combined gas and anions, as the total 
plasma sulfide (TPS). (7) Due to the rapid 
turnover of H2S, it is difficult to obtain 
meaningful measurements under various 
clinical conditions. We therefore deter-
mined TPS, which comprises H2S plus the 
dissolved and protein-bound sulfide. 
The aim of the current study was to de-
termine the levels of TPS and N-terminal 
pro brain-type natriuretic peptide (NT-
proBNP) in ambulatory hypertensive or 
diabetic patients with mild to moderate 
diastolic dysfunction and no clinical signs 
of pulmonary congestion. 
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MATERIALS AND METHODS
Study population
Twenty-four consecutive patients who 
were referred for ambulatory echocardio-
graphic examination in Celje General and 
Teaching Hospital (Celje, Slovenia) and 
showed preserved left ventricular systolic 
ejection fraction were included in this 
study, between May 2009 and May 2011. 
Informed consent was obtained from each 
patient. The study protocol conforms to 
the ethical guidelines of the 1975 Decla-
ration of Helsinki, revised in 2010, as re-
flected in the prior approval by the Insti-
tutional Human Research Committee (N° 
117bis/01/10). The study protocol was also 
approved by the National Ethical Human 
Research Committee.
The exclusion criteria included age <18 
years, valvular heart disease, congestive 
heart failure, liver failure, hypothyreosis or 
hyperthyreosis, pheochromocytoma, acute 
infection, malignancy, and psychiatric dis-
orders that limited cooperation. The addi-
tional inclusion criteria included systemic 
arterial hypertension and/or diabetes mel-
litus type 1 or type 2, as documented and 
treated for ≥5 years. All of the patients 
had to be in New York Heart Association 
(NYHA) class I or II heart failure without 
signs of pulmonary congestion. 
Estimation of diastolic function 
Echocardiographic studies were per-
formed (GE Vivid 7 or GE Vivid 6; GE 
Healthcare, USA), with trans-thoracic 
echocardiograms completed according to 
the laboratory protocol. All of the patients 
underwent a standard echocardiographic 
study to exclude other abnormalities. 
Echocardiographyc images were read by 
three blinded investigators (N.G.P, D.K., 
M.P.) for the re-measurement of all of 
the relevant parameters. These included 
ejection fraction, end diastolic volume 
(estimated using the Teicholz and Simp-
son method), (8) peak early and atrial ve-
locities of mitral inflow, early mitral inflow 
deceleration time, and septal and lateral 
mitral annular velocities (e´). Where pos-
sible, the mean for each measurement was 
taken over multiple cardiac cycles. 
The diastolic function grading was based 
on the relevant guidelines. (9) In cases 
where the parameters were non-congru-
ent, the diastolic dysfunction grade was 
established as that with the highest num-
ber of characteristic parameters, with the 
assumption of equal weighting. Thus, the 
patients with normal diastolic function 
were classified as Grade 0. The patients 
were classified as having mild diastolic 
dysfunction (Grade 1) according to: mi-
tral early/arterial ratio, <0.8; deceleration 
time, >200 ms; isovolumic relaxation time, 
100 ms; predominantly systolic for pulmo-
nary venous flow (i.e., systolic > diastolic); 
annular e´, <8 cm/s; and mean E/e´ ratio, 
<8 (septal and lateral). The patients were 
classified as having moderate diastolic 
dysfunction (Grade 2) according to: mitral 
early/arterial ratio, 0.8 to 1.5 (pseudonor-
mal), which decreased by >50% during the 
Valsalva maneuver; annular e´, <8 cm/s; 
and mean E/e´ ratio, 9 to 12. 
Total plasma sulfide and NT-proBNP meas-
urements
Total plasma sulfide and NT-proBNP were 
measured in blood samples taken from 
the patients at the time of their echocar-
diographic study. TPS was measured by 
a modified spectrophotometric method, 
(10) which was first described in 1949 by 
Fogo. (11) This method was further refined 
in 1965 by Siegel, (12) and has been used 
in other studies afterwards. (13-17) Im-
mediately after collection, blood samples 
were briefly centrifuged at 3000 rpm for 
10 min at 4°C to obtain the plasma. Two 
hundred microliters of each plasma sam-
ple was mixed with 100 μL of a pre-pre-
pared solution of 10% (v/v) trichloroacetic 
acid, and 60 μL of 1% (w/v) zinc acetate, to 
trap any dissolved H2S. The mixture was 
then frozen at -20 ºC until further analysis. 
Upon defrosting of the samples, 40 µL 20 
µM N, N-dimethyl-p-phenylenediamine 
sulfate prepared in 7.2 M HCl, and 40 
µL 30 µM FeCl3 prepared in 1.2 M HCl, 
were added. After vortexing, these sam-
ples were incubated for 20 min at room 
temperature to allow the color reaction to 
develop, and then they were centrifuged at 
9000 rpm for 5 min at 4°C, to remove the 
precipitate. The absorbance at 670 nm was 
then determined spectrophotometrically 
(Epoch microplate spectrophotometer, 
Biotek, VT, USA) for the resulting blue-
colored supernatants. The TPS concentra-
tions of the samples were then calculated 
from the absorbance calibration curve of 
known Na2S concentrations. To ensure 
accurate measurements, all of the samples 
were analyzed in triplicate, with the data 
expressed as median [range].
The NT-proBNP levels were determined 
using electrochemiluminescence im-
munoassay (Elecsys; Roche Diagnostics, 
Switzerland) according to manufacturer 
protocol. 
Statistics
The data are presented as means ±stand-
ard deviations, or as medians [range, 
minimum-maximum]. Categorical data 
were compared using c2 tests. Wilcoxon 
rank tests were used to compare data 
within groups, and Kruskal-Wallis tests 
to compare data between groups. For all 
analyses, p <0.05 was regarded as statisti-
cally significant. The data were also tested 
for rank correlations between NT-proBNP 
and TPS. The database management and all 
of the statistical analyses were performed 
using the MedCalc 12 software (MedCalc, 
Belgium).
RESULTS
Twenty-four consecutive patients were in-
cluded in this study. Their demographic 
and clinical characteristics are represent-
ed in table 1. Echocardiography data are 
represented in table 2. Nine patients had 
normal diastolic function (Grade 0), eight 
patients had Grade 1 diastolic dysfunction, 
and seven patients had Grade 2 diastolic 
dysfunction.
The data for the TPS and NT-proBNP lev-
els according to the diastolic function of 
the different patients groups are presented 
in table 3. The TPS levels decreased from 
Grade 0 to Grade 2, and were thus high-
est in patients with normal diastolic func-
tion (Grade 0) and lowest in patients with 
Grade 2 diastolic dysfunction, with statis-
tical significance reached between Grade 
0 and Grade 2 (p = 0.017) (figure 1). The 
differences in the TPS levels between Grade 
1 and Grade 2 did not reach statistical sig-
nificance (p=0,450).
Conversely, the NT-proBNP levels in-
creased from patients with normal diastolic 
function (Grade 0) to Grade 2 diastolic dys-
function (figure 2), where statistical signifi-
cance was reached again between Grade 0 
and Grade 2 (p = 0.042). 
There were no statistically significant cor-
relations found between TPS and NT-
proBNP.
DISCUSSION
The present study shows lower TPS levels 
in the plasma of patients with moderate di-
astolic dysfunction compared to those with 
normal diastolic function. Conversely, the 
NT-proBNP levels increased with increas-
ing severity of diastolic dysfunction.
Diastolic dysfunction is a pathophysiologi-
cal concept that is defined by decreased re-
laxation of the left ventricular myocardium 
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during diastole. It is often the first sign of 
ongoing pathological processes in the 
myocardium. Although the pathological 
mechanisms behind diastolic dysfunction 
are not completely understood, it is known 
to result in the accumulation of various 
proteins in the extracellular matrix, and to 
promote fibrosis. (18)
In heart failure, the plasma levels of NT-
proBNP are known to rise according to 
worsening of the clinical signs of pulmo-
nary congestion, NYHA class, and grade of 
diastolic dysfunction. (19) The echosono-
graphically defined grade of diastolic dys-
function correlates with invasively meas-
ured increased left-ventricular wall stress. 
(20) Higher plasma NT-proBNP levels 
correlate with higher ventricular wall ten-
sion and higher grade of diastolic dysfunc-
tion. (21) NT-proBNP transcription and 
secretion is activated by left ventricular 
longitudinal strain. (22) The present study 
thus confirms significantly higher plasma 
NT-proBNP levels in patients with Grade 
2 diastolic dysfunction, compared to pa-
tients with normal diastolic function. (23) 
This negative correlation was expected 
according to previous studies with NT-
proBNP, (24) and is thus confirmed by our 
investigations.
Hydrogen sulfide is an important gaseous 
transmitter that modulates vasodilatory ef-
fects in the body. (25) It also protects the 
endothelium through decreased oxidative 
stress, (26) inhibition of inflammation, 
(27) and activation of serine phosphoryla-
tion of endothelial nitric oxide synthase. 
(28) All these are well-known mechanisms 
that promote normal endothelial function. 
Failure of these mechanisms can lead to 
endothelial dysfunction, which can cause 
atherosclerosis and arterial hypertension. 
Myocardial hypertrophy is a further con-
sequence of endothelial dysfunction. 
This occurs partly as a reaction to the el-
evated afterload, and probably partly due 
to myocardial microcirculation dysfunc-
tion, myocites remodeling, changes in 
the cellular matrix, and fibrosis. (29) H2S 
has been shown to intervene in the myo-
cardial fibrosis pathway in hypertensive 
rats, although the precise mechanism has 
not been defined yet. (30) As myocardial 
hypertrophy and fibrosis are hallmarks of 
hypertonic heart failure and echocardio-
graphic signs of diastolic dysfunction, we 
feel that our data fit perfectly into the H2S 
puzzle. H2S production is down-regulated 
in hypertrophic and fibrotic myocardium, 
so we would assume that the lower levels 
of TPS seen in patients with arterial hyper-
tension and diabetes mellitus represent an 
Table 1. Demographic and clinical characteristics of the patients included in this study. 
Characteristic Datum (n = 24)
Age (years) 54 [32, 77]
Gender (female/male) 12/12
Diseases
Arterial hypertension [n (%)] 17 (70)
Diabetes mellitus [n (%)] 13 (54) 
Therapies
Angiotensin-converting enzyme inhibitor [n (%)] 13 (54)
Beta-blocker [n (%)] 7 (30)
Angiotensin receptor blocker [n (%)] 2 (8)
Diuretic [n (%)] 6 (25)
Spironolactone [n (%)] 0 (0)
Other anti-hypertensive therapy [n (%)] 6 (25)
Physiology 
Heart rate (bpm) 65
Systolic arterial pressure (mmHg) 134 ±17
Diastolic arterial pressure (mmHg) 74 ±14
Laboratory analyses
Creatinine (µmol/L) 79 ±21
NT-proBNP (ng/L) 319.3 ±786
Table 2. Echocardiographic data of the patients included in this study.
Analysis Unit Datum (n = 24)
Systolic function
End diastolic volume (Simpson) mL 77 ±24 [63-78]
Left ventricular ejection fraction (Simpson)
% 67 ±11 [60-73]
(Teicholz) % 69 ±9 [63-76]
Diastolic function
Early peak velocity of mitral inflow A m/s 0.9 ±0.2 [0.7-1.1]
Late peak velocity of mitral inflow E m/s 0.87 ±0.12 [0.78-0.91]
Early mitral inflow deceleration time ms 194 ±40 [178-217]
Mitral early/late velocity ratio -- 1.1 ±0.3 [0.8-1.3]
Mitral septal annular velocity e´  cm/s 9.3 ±2.9 [7.7-10.9]
Mitral lateral annular velocity e´ cm/s 12.2 ±3.5 [10.4-13.6]
Table 3. Patient total plasma sulfide and NT-proBNP levels according to diastolic function.
Diastolic function n Total plasma sulfide (µM) NT-proBNP (pg/L)
Grade 0 9 1.5 [0.4-2.1] 63 [15-141]
Grade 1 8 0.8 [0.0-3.3] 106 [19-184]
Grade 2 7 0.3 [0.0-1.8]* 147 [36-342]*
Data are medians [range]; * p <0.05, compared to Grade 0 (Wilcoxon rank test)
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important sign of the ongoing processes 
at the cytological level. Although this does 
not show significant effects on arterial 
pressure, it does affect the signaling path-
ways that lead to vascular and myocardial 
remodeling. (31) 
Drachuk et al. (32) showed a direct cor-
relation between low H2S levels and dias-
tolic dysfunction due to aging. As aging is 
also linked to lower NO production, they 
demonstrated that supplementation of 
H2S improved myocardial relaxation and 
decreased diastolic dysfunction. Therefore, 
H2S can be used as an independent marker 
for early diastolic dysfunction in hyper-
tonic patients, which will thus call for im-
mediate action with the relevant approved 
treatment. 
On a more optimistic note, H2S offers 
a new treatment option. (33) The active 
metabolite in garlic, allicin, is promptly 
degraded into organic diallyl polysulfides 
that are potent H2S donors in the presence 
of thiols. It has been known for centuries 
that garlic has substantial medicinal ef-
fects and it is considered to be one of the 
best disease-preventive foods. (34) Garlic 
reduces the risks associated with cardio-
vascular disease by lowering of cholesterol 
level, inhibition of platelet aggregation, 
and lowering of blood pressure. H2S and 
its decreased production have been pro-
posed to have an important role in the 
pathogenesis of arterial hypertension. (35) 
Regular aerobic exercise was shown to 
raise H2S production in the body. There-
fore, exercise is also a potential treatment 
option for vascular remodeling and ath-
erosclerosis, through its provision of H2S 
donors. (36) Once again, diet and exercise 
are important in the maintenance of health 
and the prevention of many diseases, in-
cluding cardiovascular disease.
As H2S is a gas, this might cause difficul-
ties for its measurement under various 
clinical conditions. A recent report has 
also confirmed that H2S is short-lived, 
and can even be undetectable in normal 
physiological states. (37) Several different 
methods have been used to measure H2S 
and/or sulfide concentrations in biologi-
cal systems, which have included: head-
space gas analysis; derivatization meth-
ods, such as entafluorobenzyl bromide 
or N,N-dimethyl-p-phenylenediamine 
to form methylene blue; spectrophotom-
etry; a monobromobimane-based assay; 
and direct measurements in solution with 
a silver sulfide or polarographic sensor. 
Due to this wide variety of experimen-
tal methods used, highly variable data 
have been obtained regarding the abso-
lute concentrations of sulfide in the blood 
and tissues. Thus, there appears to be no 
general consensus in the field as to which 
measurement(s) correctly define(s) the 
‘biologically available H2S/ sulfide’. (38) In 
the present study, we used a method to de-
termine the TPS levels (i.e., H2S, dissolved 
sulfide, acid labile sulfide), to estimate the 
larger pool of sulfur molecules.
The main factor that might limit the inter-
pretation of our findings here is the low 
number of patients enrolled, which is part-
ly attributable to the recruitment from a 
single secondary heart failure clinic, as well 
as the very often newly diagnosed diabetes 
mellitus at baseline. Our data thus require 
confirmation in larger studies. Further-
more, studies are needed to evaluate the 
prognostic value of serial TPS measure-
ments, and the effects of H2S therapy.
In conclusion, our study has revealed sig-
nificantly lower TPS levels and higher 
plasma NT-proBNP levels in patients with 
diastolic dysfunction Grade 2 compared to 
patients with normal diastolic function.
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Figure 1. Patient total plasma sulfide levels according to diastolic 
function.
Figure 2. Patient plasma NT-proBNP levels according to diastolic 
function.
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